Sanfilippo syndrome

Mucopolysaccharidosis characterized by a deficiency of the lysosomal enzyme resulting in incomplete breakdown of the heparan sulfate sugar chain

Sanfilippo Syndrome (MPS III)
Synonyms	Mucopolysaccharidosis III; MPS III
Pronounce	/ˌsanfɪˈliːpəʊz/
Field
Symptoms	Progressive intellectual disability; hyperactivity; dementia; loss of mobility
Complications
Onset	Birth; symptoms usually become apparent between ages 2-6
Duration	Lifelong
Types	Sanfilippo Syndrome Types A, B, C, and D
Causes	Inherited enzyme deficiency
Risks
Diagnosis	MPS urine screen (initial test), confirmed by blood test
Differential diagnosis
Prevention
Treatment
Medication
Prognosis	Lifespan is reduced; most patients survive until the early teenage years, but some may reach their 30s
Frequency	1 in 70,000<ref name=NINDS> Mucopolysaccharidoses Fact Sheet(link). {{{website}}}. National Institute of Neurological Disorders and Stroke. 15 Nov 2017. </ref>
Deaths

Definition

Sanfilippo syndrome, also known as mucopolysaccharidosis type III (MPS III), is a rare autosomal recessive lysosomal storage disease that primarily affects the brain and spinal cord. It is caused by a buildup of large sugar molecules called glycosaminoglycans (AKA GAGs, or mucopolysaccharides) in the body's lysosomes.

Summary

Affected children generally do not show any signs or symptoms at birth. In early childhood, they begin to develop developmental disability and loss of previously learned skills. In later stages of the disorder, they may develop seizures and movement disorders. Patients with Sanfilippo syndrome usually live into adolescence or early adulthood.<ref name=GeneticsHomeReference>

Mucopolysaccharidosis type III(link). {{{website}}}. Genetics Home Reference. March 2017.

</ref>

Cause

• Mutations in the GNS, HGSNAT, NAGLU, and SGSH genes cause MPS III.
• These genes provide instructions for making enzymes involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs).
• GAGs were originally called mucopolysaccharides, which is where this condition gets its name. The GNS, HGSNAT, NAGLU, and SGSH enzymes are involved in the step-wise breakdown of a subset of GAGs called heparan sulfate.

• MPS IIIA is caused by mutations in the SGSH gene, and
• MPS IIIB is caused by NAGLU gene mutations.
• Mutations in the HGSNAT gene result in MPS IIIC, and GNS gene mutations cause MPS IIID.

Gene mutations

• Mutations in these genes reduce or eliminate enzyme function.
• A lack of any one of these enzymes disrupts the breakdown of heparan sulfate.
• As a result, partially broken down heparan sulfate accumulates within cells, specifically inside the lysosomes.
• Lysosomes are compartments in the cell that digest and recycle different types of molecules.
• Conditions such as MPS III that cause molecules to build up inside the lysosomes are called lysosomal storage disorders.
• Researchers believe that the accumulation of GAGs interferes with the functions of other proteins inside the lysosomes and disrupts the normal functions of cells. It is unknown why the buildup of heparan sulfate mostly affects the central nervous system in MPS III.

Inheritance

Autosomal recessive inheritance, a 25% chance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Signs and symptoms

The disease manifests in young children. Symptoms usually begin to appear between 2 and 6 years of age.<ref name=Guide/> Affected infants appear normal, although some mild facial dysmorphism may be noticeable. Of all of the MPS diseases, Sanfilippo syndrome produces the fewest physical abnormalities. After an initial symptom-free interval, patients usually present with a slowing of development and/or behavioral problems, followed by progressive intellectual decline resulting in severe dementia and progressive motor disease.<ref>,

 Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype, 
 Inherit Metab Dis, 
 
 Vol. 10.1007/s10545-010-9199-y(Issue: 6),
 pp. 759–767,
 DOI: 10.1007/s10545-010-9199-y,
 PMID: 20852935,
 PMC: 2992652,
 
 Full text,</ref> Acquisition of speech is often slow and incomplete.

The disease progresses to increasing behavioral disturbance including temper tantrums, hyperactivity, destructiveness, aggressive behavior, pica, difficulties with toilet training, and sleep disturbance. As affected children initially have normal muscle strength and mobility, the behavioral disturbances may be difficult to manage. The disordered sleep in particular presents a significant problem to care providers.

In the final phase of the illness, children become increasingly immobile and unresponsive, often require wheelchairs, and develop swallowing difficulties and seizures. The life-span of an affected child does not usually extend beyond late teens to early twenties.

Individuals with MPS Type III tend to have mild skeletal abnormalities; osteonecrosis of the femoral head may be present in patients with the severe form. Optic nerve atrophy, deafness, and otitis can be seen in moderate to severe individuals. Other characteristics include coarse facial features, thick lips, synophrys, and stiff joints.

It is difficult to clinically distinguish differences among the four types of Sanfilippo syndrome. However, type A is usually the most severe subtype, characterized by earliest onset, rapid clinical progression with severe symptoms, and short survival.<ref name=Andrade>,

 Sanfilippo syndrome: Overall review, 
 Pediatrics International, 
 
 Vol. 57(Issue: 3),
 pp. 331–8,
 DOI: 10.1111/ped.12636,
 PMID: 25851924,</ref> The median age of death for children afflicted with type A is 15.4 years, ±4.1 years.<ref name=Tardieu>

Tardieu, Marc,

 Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human SGSH and SUMF1 cDNAs in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I/II Trial , 
 , 
  
 February 2014,

</ref>

It is important that simple and treatable conditions such as ear infections and toothaches not be overlooked because of behavior problems that make examination difficult. Children with MPS type III often have an increased tolerance to pain. Bumps, bruises, or ear infections that would be painful for other children often go unnoticed in children with MPS type III. Some children with MPS type III may have a blood-clotting problem during and after surgery.<ref name="Guide">

A Guide to Understanding MPS III(link). {{{website}}}.

</ref>

Mechanism

Structure of heparan sulfate, one of the molecules that builds up in the tissues of people with Sanfilippo syndrome

Glycosaminoglycans (GAGs) are chains of sugar molecules. They are found in the extracellular matrix and the cell membrane, or stored in the secretory granules. GAGs are stored in the cell lysosome, and are degraded by enzymes such as glycosidases, sulfatases, and acetyltransferases. Deficiency in these enzymes lead to the four subtypes of MPS III.<ref name=Andrade />

Diagnosis

Sanfilippo Syndrome Types A, B, C, and D are considered to be clinically indistinguishable, although mutations in different genes are responsible for each disease. The following discussion is therefore applicable to all four conditions.

A urinalysis can show elevated levels of heparan sulfate in the urine.<ref name=MedLinePlus/> All four types of Sanfilippo syndrome show increased levels of GAGs in the urine; however, this is less true of Sanfilippo syndrome than other MPS disorders. Additionally, urinary GAG levels are higher in infants and toddlers than in older children. In order to avoid a false negative urine test due to dilution, it is important that a urine sample be taken first thing in the morning. The diagnosis may be confirmed by enzyme assay of skin fibroblasts and white blood cells, as well as gene sequencing. Prenatal diagnosis is possible by chorionic villus sampling or amniocentesis.<ref name=Medscape/>

Treatment

Treatment remains largely supportive. The behavioral disturbances of MPS-III respond poorly to medication. If an early diagnosis is made, bone marrow replacement may be beneficial. Although the missing enzyme can be manufactured and given intravenously, it cannot penetrate the blood–brain barrier and therefore cannot treat the neurological manifestations of the disease. Along with many other lysosomal storage diseases, MPS-III exists as a model of a monogenetic disease involving the central nervous system.

Several promising therapies are in development. Gene therapy in particular is under Phase I/II clinical trial in France since October 2011 under the leadership of Paris-based biotechnology company Lysogene.<ref>Koberstein, Wayne,

 Lysogene: Mother of Invention, 
 Life Science Leader, 
 
 
 
 
 
 
 
 Full text,</ref><ref>Intracerebral Gene Therapy for Sanfilippo Type A Syndrome on clinicaltrials.gov</ref> Other potential therapies include chemical modification of deficient enzymes to allow them to penetrate the blood–brain barrier, stabilisation of abnormal but active enzyme to prevent its degradation, and implantation of stem cells strongly expressing the missing enzyme. For any future treatment to be successful, it must be administered as early as possible. Currently MPS-III is mainly diagnosed clinically, by which stage it is probably too late for any treatment to be very effective. Neonatal screening programs would provide the earliest possible diagnosis.

The flavonoid genistein decreases the accumulation of GAGs.<ref>http://www.bgo.ug.gda.pl/kbm/dmb/staff/gw.htm</ref> In vitro, animal studies and clinical experiments suggest that the symptoms of the disease may be alleviated by an adequate dose of genistein.<ref name="Piotrowska-2006">,

 Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses, 
 European Journal of Human Genetics, 
 
 Vol. 14(Issue: 7),
 pp. 846–52,
 DOI: 10.1038/sj.ejhg.5201623,
 PMID: 16670689,</ref> Despite its reported beneficial properties, genistein also has toxic side effects.<ref name="Jin-2007">, 
 Genistein and daidzein induce neurotoxicity at high concentrations in primary rat neuronal cultures, 
 J Biomed Sci, 
 
 Vol. 14(Issue: 2),
 pp. 275–84,
 DOI: 10.1007/s11373-006-9142-2,
 PMID: 17245525,</ref>

Several support and research groups have been established to speed the development of new treatments for Sanfilippo syndrome.<ref>Cure Sanfilippo Foundation, funding research to accelerate discovery of a cure to Sanfilippo Syndrome</ref><ref>Jonah's Just Begun - Foundation to Cure Sanfilippo, Inc.</ref><ref>Phoenix Nest, Inc., a biotech company seeking treatments and cures for Sanfilippo Syndrome</ref><ref>Phunk Phenomenon HipHop For Hope, a dance crew in Boston raising awareness for Sanfilippo Syndrome</ref> <ref>Team Sanfilippo Foundation, a medical research foundation created by parents of children with Sanfilippo Syndrome</ref>

Prognosis

According to a study of patients with Sanfilippo syndrome, the median life expectancy varies depending on the subtype. In Sanfilippo syndrome type A, the mean age at death (± standard deviation) was 15.22 ± 4.22 years. For Type B, it was 18.91 ± 7.33 years, and for Type C it was 23.43 ± 9.47 years. The mean life expectancy for Type A has increased since the 1970s.<ref name="mortality">,

 Mortality in patients with Sanfilippo syndrome, 
 Orphanet Journal of Rare Diseases, 
 
 Vol. 12(Issue: 1),
 pp. 168,
 DOI: 10.1186/s13023-017-0717-y,
 PMID: 29061114,
 PMC: 5654004,</ref>

Epidemiology

Incidence of Sanfilippo syndrome varies geographically, with approximately 1 case per 280,000 live births in Northern Ireland,<ref>Nelson J,

 Incidence of the mucopolysaccharidoses in Northern Ireland, 
 Hum. Genet., 
 
 Vol. 101(Issue: 3),
 pp. 355–8,
 DOI: 10.1007/s004390050641,
 PMID: 9439667,</ref> 1 per 66,000 in Australia,<ref name=meikle>, 
 Prevalence of lysosomal storage disorders, 
 JAMA, 
 
 Vol. 281(Issue: 3),
 pp. 249–54,
 DOI: 10.1001/jama.281.3.249,
 PMID: 9918480,</ref> and 1 per 50,000 in the Netherlands.<ref>, 
 The frequency of lysosomal storage diseases in The Netherlands, 
 Hum. Genet., 
 1999,
 Vol. 105(Issue: 1–2),
 pp. 151–6,
 DOI: 10.1007/s004390051078,
 PMID: 10480370,</ref>

The Australian study estimated the following incidences for each subtype of Sanfilippo syndrome:

Sanfilippo syndrome type	Approximate incidence	Percentage of cases	Age of onset
A	1 in 100,000<ref name=meikle/>	60%	1.5-4
B	1 in 200,000<ref name=meikle/>	30%	1-4
C	1 in 1,500,000<ref name=meikle/>	4%	3-7
D	1 in 1,000,000<ref name=meikle/>	6%	2-6

History

The condition is named after Sylvester Sanfilippo, the pediatrician who first described the disease in 1963.<ref name=Guide/><ref name="Medscape"> Defendi, Germaine L.. Sanfilippo Syndrome (Mucopolysaccharidosis Type III)(link). {{{website}}}. Medscape. 23 May 2018.

</ref><ref>Sanfilippo, S. J.; Podosin, R.; Langer, L. O., Jr.; Good, R. A. : Mental retardation associated with acid mucopolysacchariduria (heparitin sulfate type). J. Pediat. 63: 837-838, 1963.</ref>

Caregiver impact

Caregivers for children with Sanfilippo Syndrome face a unique set of challenges because of the disease's complex nature. There is little understanding among clinicians of the family experience of caring for patients with Sanfilippo and how a caregiver's experiences change and evolve as patients age. The burden and impact on caregivers' quality of life is poorly defined and best-practice guidance for clinicians is lacking.<ref name="Shapiro et al">,

 Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data, 
 Orphanet Journal of Rare Diseases, 
 
 Vol. 14(Issue: 1),
 pp. 168,
 DOI: 10.1186/s13023-019-1150-1,
 
 
 
 Full text,  Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.</ref>

A best-practice guidance to help clinicians understand the challenges caregivers face was published July 2019 in the Orphanet Journal of Rare Diseases by a group of international clinical advisors with expertise in the care of pediatric patients with Sanfilippo, lysosomal storage disorders, and life as a caregiver to a child with Sanfilippo.<ref name="Shapiro et al"/>

The group reviewed key aspects of caregiver burden associated with Sanfilippo B by identifying and quantifying the nature and impact of the disease on patients and caregivers. Recommendations were based on findings from qualitative and quantitative research.<ref name="Shapiro et al"/>

The article's authors reported that: "Providing care for patients with Sanfilippo B impinges on all aspects of family life, evolving as the patient ages and the disease progresses. Important factors contributing toward caregiver burden include sleep disturbances, impulsive and hyperactive behavior, and communication difficulties...Caregiver burden remained high throughout the life of the patient and, coupled with the physical burden of daily care, had a cumulative impact that generated significant psychological stress."<ref name="Shapiro et al"/>

Additionally, the authors call for changing the narrative associated with Sanfilippo: "The panel agreed that the perceived aggressive behavior of the child may be better described as 'physical impulsiveness' and is often misunderstood by the general public. Importantly, the lack of intentionality of the child’s behavior is recognized and shared by parents and panel members...Parents may seek to protect their child from public scrutiny and avoid situations that many engender criticism of their parenting skills."<ref name="Shapiro et al"/>

See also

• Mucopolysaccharidosis
• Hurler syndrome (MPS I)
• Hunter syndrome (MPS II)
• Morquio syndrome (MPS IV)
• List of neurological conditions and disorders

External links

• Cure Sanfilippo Foundation
  • A one-page handout about the clinical symptoms and testing for Sanfilippo Syndrome

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia